GT128, a CYCLIN DEPENDENT KINASE 4/6 INHIBITOR, IN COMBINATION WITH ETOPOSIDE AND CARBOPLATIN FOR EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC): PRELIMINARY RESULTS

CAIO M. S. ROCHA, PATRICK J. ROBERTS, VICTOR M. PREGO, STEPHEN G. DIVERS, MELANIE THOMAS, RALPH BOCCIA, TIMOTHY WEBB, KATIE STABELER, KARENANN M. MAKHULI, RAJESH K. MALIK, RAJALD JUMALY, GEOFFREY I. SHAPIRO

OBJECTIVES

Assesses the dose-limiting toxicities (DLT), safety and tolerability, pharmacological properties, pharmacokinetics (PK) and anti-tumor activity of GT128 in combination with etoposide and Carboplatin (EP).

METHODS

In a Phase I/II healthy normal volunteer (HNV) study (NCT02241500), GT128 advances intravenously was well tolerated, no dose limiting toxicities or serious adverse events (SAEs) were observed. GT128 in normal volunteers demonstrated that GT128-induced GI cycle-cell arrest renders minor tissue to chemotherapy optimally, allowing

RESULT

In this ongoing study, the combination of GT128 with EP is well tolerated, without any episodes of febrile neutropenia or treatment-related SAEs. The most common adverse events were hematologic toxicities (anemia, neutropenia, thrombocytopenia), nonhematologic (fatigue, nausea, vomiting) and grade 1-2 acneiform rash, grade 1-2 anorexia. No grade 4 SAEs were observed.

CONCLUSIONS

In this study, the combination of GT128 and EP is well tolerated, without any episodes of febrile neutropenia or treatment-related SAEs. The most common adverse events were hematologic toxicities (anemia, neutropenia, thrombocytopenia), nonhematologic (fatigue, nausea, vomiting). No grade 4 SAEs were observed. The combination of GT128 with EP is associated with minimal liver function impairment.

ACKNOWLEDGMENTS

We thank and acknowledge all the patients, their families, and caregivers participating in this study. Wendy Arners, an employee of GI Therapeutics, Inc., assisted with this poster preparation.